-
1
An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamo...
Published 2025-01-01Subjects: “…azacitidine…”
Get full text
Article